Molecular characterization of two high-level ceftriaxone-resistant Neisseria gonorrhoeae isolates detected in Catalonia, Spain

Abstract

This is the first reported case of high-level extended-spectrum cephalosporin-resistant N. gonorrhoeae transmission. The molecular typing and MDR genotype suggest possible European spread of this strain, highlighting the need for surveillance and the importance of testing the susceptibility of N. gonorrhoeae to extended-spectrum cephalosporins.

Modern aspects of epidemiological surveillance of gonococcal infection spread

“…В 2011 г. был впервые получен штамм N. gonorrhoeae, высокорезистентный к цефалоспоринам III поколения (МПК 2-4 мг/л, Киото, Япония) [72], затем во Франции [73], Испании [74]. По данным ВОЗ 2010 г.…”

Antibiotic Susceptibility of Neisseria gonorrhoeae Isolates from Guangzhou, China, during 2002–2011

“…Treatment failure with extended-spectrum cephalosporins such as oral cefixime has been recently documented in Japan and several European countries (4)(5)(6). Furthermore, treatment failure with injectable ceftriaxone for pharyngeal gonorrhea has been reported (7)(8)(9). The continuing spread of antibiotic-resistant N. gonorrhoeae has posed challenges for successful treatment worldwide.…”

Polymerase chain reaction-based screening for the ceftriaxone-resistant Neisseria gonorrhoeae F89 strain

“…With the emergence of the ceftriaxone-resistant and extensively-drug resistant (XDR) Neisseria gonorrhoeae strains H041 in Japan [1] and F89 in France and Spain [2,3], there exists a real threat that such strains may emerge and spread worldwide. Molecular characterisation of these strains has implicated mutations in the penicillin binding protein 2 (PBP2) in conferring resistance to ceftriaxone [1,2].…”

“…The Japanese H041 (ceftriaxone MIC=2 to 4 mg/L) featured several novel substitutions on the mosaic PBP2, of which two (A311V and T316S) have been experimentally shown to contribute to ESC resistance [1]. Similarly the European F89 strain (ceftriaxone MIC=1 to 2 mg/L) harboured an amino acid substitution at position 501 (A501P) of the mosaic PBP2, resulting in ESC resistance [2,3]. The contribution of other substitutions at position 501 of PBP2, especially A501V but also A501T, towards reduced susceptibility to ESCs has also been shown [4][5][6][7].…”